EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

Steven Wang iD, Marcel Nijland iD, Leonie Strobbe, Margriet Oosterveld iD, Rinske Boersma, Harry Koene, Clara Klerk, Eva de Jongh, Ad Koster, Hans Pruijt iD, Marjolein van der Poel, Erik van Werkhoven iD und 9 weitere

Journal of Clinical Oncology · 10.02.2026 · 44 (5) · 400-409

DOI: 10.1200/jco-25-01712 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2026. Verfasst von Steven Wang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC-Location Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE End-of-treatment (EOT) response evaluation by positron emission tomography (PET) remains suboptimal in patients with large B-cell lymphoma (LBCL), because of its limited positive predictive value (PPV). Circulating tumor DNA (ctDNA)—based measurable residual disease (MRD) detection offers a minimally invasive approach and may improve prognostication. We prospectively evaluated EOT MRD using phased variant enrichment and detection sequencing (PhasED-Seq) in patients with first-line LBCL. METHODS Patients were enrolled in the HOVON-902 prospective cohort and received curative-intent first-line treatment. Phased variants (PVs) were identified and tracked using tumor biopsies or pretreatment plasma. The prognostic significance of EOT ctDNA-MRD status in progression-free survival (PFS) and overall survival (OS) was compared with that of the International Prognostic Index (IPI) and EOT PET-computed tomography (CT). RESULTS PV identification was successful in 134 of 136 (99%) using either tissue or plasma. At EOT, 83% of patients were MRD-negative and 17% of patients were MRD-positive. MRD positivity was strongly associated with inferior outcomes: the 3-year PFS was 17% in MRD-positive versus 85% in MRD-negative patients (hazard ratio [HR], 9.8 [95% CI, 5.1 to 19]; P = 9.63 × 10 −12 ), and the OS was 43% versus 92%, respectively (HR, 7.7 [95% CI, 3.4 to 17.4]; P = 1.27 × 10 −6 ). In multivariate analysis, MRD was an independent prognostic factor when controlling for IPI and EOT PET-CT. MRD positivity had a higher PPV for 2-year PFS than positive PET (68% v 56%, P ≤ .001), whereas negative predictive value was similar between negative MRD and PET (89% v 88%, P = .71). MRD positivity was associated with a significantly higher relapse risk within both complete metabolic response (CMR) and non-CMR subgroups. CONCLUSION This study validates ultrasensitive ctDNA-MRD detection using PhasED-Seq in a uniformly treated, prospective real-world LBCL cohort. These findings support further evaluation of MRD integration into clinical response assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorHumansNeoplasm, ResidualMaleFemaleMiddle AgedProspective StudiesAgedAdultPositron Emission Tomography Computed TomographyAged, 80 and overProgression-Free SurvivalPrognosis

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, Amsterdam UMC-Location Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Department of Pathology, Amsterdam UMC-Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA.
  • University Medical Center Groningen, Groningen, The Netherlands.
  • Gelre Hospital, Zutphen, The Netherlands.
  • Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

ORCID-Profile: Steven Wang, Marcel Nijland, Margriet Oosterveld, Hans Pruijt, Erik van Werkhoven, Michiel Pegtel, Sierra Love Stowell, Ash A Alizadeh, David M Kurtz, Martine E D Chamuleau

Zitieren

APA

Wang, S., Nijland, M., Strobbe, L., Oosterveld, M., Boersma, R., Koene, H., Klerk, C., de Jongh, E., Koster, A., Pruijt, H., van der Poel, M., van Werkhoven, E., Zanders, H., Dinmohamed, A., Pegtel, M., Meek, S., Stowell, S. L., Warinske, H., Alizadeh, A. A., …, & Chamuleau, M. E. D. (2026). Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. Journal of Clinical Oncology, 44(5), 400-409. https://doi.org/10.1200/jco-25-01712

Vancouver

Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, et al. Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. Journal of Clinical Oncology. 2026;44(5):400-409. doi:10.1200/jco-25-01712

BibTeX
@article{Wang2026,
  author = {Wang, Steven and Nijland, Marcel and Strobbe, Leonie and Oosterveld, Margriet and Boersma, Rinske and Koene, Harry and Klerk, Clara and de Jongh, Eva and Koster, Ad and Pruijt, Hans and van der Poel, Marjolein and van Werkhoven, Erik and Zanders, Helma and Dinmohamed, Avinash and Pegtel, Michiel and Meek, Stephanie and Stowell, Sierra Love and Warinske, Hayley and Alizadeh, Ash A and Kurtz, David M and Chamuleau, Martine E D},
  title = {Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {5},
  pages = {400--409},
  doi = {10.1200/jco-25-01712}
}
Kostenlos starten →